Dyax Corp. and Merck KGaA Enter Into License Agreement for Discovery of Therapeutic Antibodies and Peptides
Dyax Corp. announced that it has granted a non-exclusive license to its proprietary phage display libraries to Merck KGaA for the discovery and development of therapeutic antibodies and peptides. Under the terms of the agreement, Dyax receives an upfront technology license fee from Merck, as well as annual maintenance fees, clinical milestone payments and royalties on net sales of any products that may result from Merck's use of the Dyax libraries. In addition, Merck has an option for Dyax to perform funded research on its behalf. The agreement provides Merck with a license to Dyax's antibody and peptide phage display technology and patent rights, as well as sublicenses to relevant third-party antibody phage display patents that may be used with Dyax's technology.
Other news from the department business & finance

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Merck Welcomes Ten New Startups to its Innovation Center
Toray to Increase Production Capacity of ABS Resin Toyolac in Malaysia - Total Investment of 10 Billion Yen
Kemira: Tikkurila has acquired rest of shares in its industrial coatings companies in Russia

New approach improves ability to predict metals' reactions with water
BOC expands in Brazil
DOE-funded research projects win 46 R&D 100 Awards for 2009
AkzoNobel to outline new strategy - Plan for enhanced value creation
Tolerability Demonstrated by ABX-EGF as Monotherapy in Advanced Cancers

MEDELEC MINIMECA SA - Puidoux, Switzerland

Scientists develop fully solar-driven autonomous chemical mini-plant - Production of fine chemicals in remote locations on Earth, and possibly even on Mars - also facade could make chemicals
Environmental contaminants in foodstuffs - BfR research project on the intake of heavy metals and dioxins completed
